Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Halita is a specialized oral hygiene product line designed for the treatment and prevention of halitosis (bad breath). Developed by Dentaid and distributed in France by Laboratoires Crinex, the range includes mouthwash, toothpaste, and spray formulations. The primary mechanism of action involves a synergistic combination of cetylpyridinium chloride (CPC), a broad-spectrum antiseptic that reduces the bacterial load and dental plaque formation, and zinc lactate, which chemically neutralizes volatile sulfur compounds (VSCs) produced by anaerobic bacteria on the tongue. Additionally, the toothpaste formulation typically includes fluoride to provide protection against dental caries. Halita is intended for daily topical use in the oral cavity to maintain oral health and ensure fresh breath.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Halita.